Document Detail

Antiviral activity of diverse classes of broad-acting agents and natural compounds in HHV-6-infected lymphoblasts.
MedLine Citation:
PMID:  17276373     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: HHV-6 replication requires complex and poorly understood interactions between viral and cellular factors. OBJECTIVES: Several natural compounds or broad-acting pharmacological agents were studied in an attempt to discover new targets for anti-HHV-6 therapy. STUDY DESIGN: The antiviral activity was determined in human T-lymphoblasts, using HHV-6A (GS)-infected HSB-2 cells, HHV-6B (Z29)-infected MOLT-3 cells and HHV- 6B (HST)-infected MT4 cells. Virus replication was measured by CPE and qPCR assay. Foscarnet was included as the reference compound. RESULTS: Among the 15 natural compounds tested, only 'red marine algae' (an extract rich in sulfated polysaccharides) exhibited strong activity when added during virus adsorption. Among the broad-acting pharmacological agents, chloroquine, artemisinin, hypericin, ribavirin, resveratrol and glycyrrhizic acid were all inactive. Amantadine produced a reproducible inhibition of HHV-6 replication, albeit at relatively high concentrations. Except for lamotrigine, which was moderately active against HHV-6B, several antiepileptic drugs were shown to have no activity. We included several compounds which we previously described as potent HHV-6 inhibitors, i.e., the non-nucleoside inhibitor CMV423 and the acyclic nucleoside phosphonate analogues cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-3-deazaadenine. The latter compound exhibited remarkable anti-HHV-6 activity. CONCLUSION: Further optimization of compounds belonging to diverse classes of antiherpetic agents, for their specific action against HHV-6, is warranted.
Lieve Naesens; Pascale Bonnafous; Henri Agut; Erik De Clercq
Related Documents :
12534963 - Discrepant results in the interpretation of hiv-1 drug-resistance genotypic data among ...
12829813 - Infectivity and replication capacity of drug-resistant human immunodeficiency virus typ...
17285463 - Structure-based drug design of new leads for phosphatase research.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology     Volume:  37 Suppl 1     ISSN:  1386-6532     ISO Abbreviation:  J. Clin. Virol.     Publication Date:  2006 Dec 
Date Detail:
Created Date:  2007-02-05     Completed Date:  2007-08-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9815671     Medline TA:  J Clin Virol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  S69-75     Citation Subset:  IM    
Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antiviral Agents / pharmacology*
Cell Line
Cytopathogenic Effect, Viral / drug effects
DNA, Viral / biosynthesis
Herpesvirus 6, Human / drug effects*,  physiology
Lymphocytes / virology*
Polymerase Chain Reaction
Virus Replication / drug effects
Reg. No./Substance:
0/Antiviral Agents; 0/DNA, Viral

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Human herpesvirus 6B inhibits cell proliferation by a p53-independent pathway.
Next Document:  HHV-6 DNA in peripheral blood mononuclear cells after liver transplantation.